Enterprise Value
277.9M
Cash
92.63M
Avg Qtr Burn
-16.03M
Short % of Float
4.96%
Insider Ownership
12.34%
Institutional Own.
61.81%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
DANYELZA® (naxitamab-gqgk) Details Spinal cord tumor, Neuroblastoma, Spinal cord injury, Cancer, Osteosarcoma | Approved Quarterly sales | |
Omburtamab (monoclonal antibody 8H9 (131I-8H9)) Details Brain tumor, Spinal cord tumor | BLA FDA meeting | |
Naxitamab + GM-CSF Details Cancer, Neuroblastoma | Phase 2 Data readout | |
GD2-SADA Details Cancer, Solid tumor/s, Melanoma, Small cell lung cancer, Sarcoma | Phase 1 Data readout | |
GD2-GD3 Vaccine Details Rare diseases, Spinal cord tumor, Neuroblastoma, Cancer | Failed Discontinued |